Rob de Ree(Netherlands · ♂)— A Dutch biotech executive key to Dezima's roughly 1 billion euro sale to Amgen, who co-founded NorthSea Therapeutics in 2017 as CEO to develop SEFA fatty-acid drugs for metabolic and fibrotic diseases.
Patrick Round(United Kingdom · ♂)— A clinician and former Dezima executive who became NorthSea's CMO, applying his metabolic-disease drug experience to its NASH pipeline.
David A. Fraser(♂)— A scientific co-founder of NorthSea Therapeutics behind its Structurally Engineered Fatty Acid (SEFA) technology platform.
Hilde Steineger(Norway · ♀)— A scientific co-founder of NorthSea who brought expertise in fatty-acid and lipid science to the company's SEFA drug platform.
Tore Skjaeret(Norway · ♂)— A scientific co-founder of NorthSea Therapeutics contributing to its structurally engineered fatty-acid drug development.
Funding history
Date
Round
Amount
Dec 2021
Series C
Amsterdam biotech NorthSea Therapeutics raised USD 80M in Series C co-led by Ysios Capital and Forbion Growth to advance its NASH and metabolic disorder pipeline.
$80M
Investors
Tap an investor to see what else they have backed.